No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients

HIV Medicine

Volumn 13, Issue 7, 2012, Pages 448-452

  Van Welzen, B J ^a   Mudrikova, T ^a   Arends, J E ^a   Hoepelman, Aim ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Efavirenz; Hepatotoxicity; Long term; Nevirapine; Nonnucleoside reverse transcriptase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COINFECTION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863194694     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.00995.x     Document Type: Article

References (15)

1. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
2. Brück S, Witte S, Brust J etal. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13: 343-348.
3. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29: 340-345.
4. Nunez M, Soriano V, Martin-Carbonero L etal. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 2002; 3: 186-194.
5. Reliquet V, Allavena C, Francois-Brunet C etal. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med 2006; 7: 431-436.
6. Rodriguez-Arrondo F, Aguirrebengoa K, Portu J etal. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Curr HIV Res 2009; 7: 526-532.
7. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245: 194-205.
8. Medrano J, Barreiro P, Tuma P etal. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev 2008; 10: 110-115.
9. Colafigli M, Di GS, Bracciale L etal. Long-term follow-up of nevirapine-treated patients in a single-centre cohort. HIV Med 2009; 10: 461-469.
10. Reliquet V, Allavena C, Morineau-Le HP, Mounoury O, Raffi F. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. HIV Clin Trials 2010; 11: 110-117.
11. Bonjoch A, Paredes R, Domingo P etal. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-329.
12. Monforte AA, Bugarini R, Pezzotti P etal. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28: 114-123.
13. Lebray P, Benhamou Y, Pol S, Myers RP, Poynard T, Di MV. NNRTI-related or -unrelated hepatotoxicity? Hepatology 2002; 36: 512-513.
14. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44 (Suppl): S132-S139.
15. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59: 342-346.